Bartter's and Gitelman's Syndromes

1. Clinical Overview

Summary

Bartter's and Gitelman's syndromes are autosomal recessive renal tubular disorders characterized by the triad of hypokalaemia, metabolic alkalosis, and normal or low blood pressure. They represent inherited "salt-wasting" tubulopathies that biochemically mimic chronic diuretic use. [1,2]

These conditions are distinguished by their site of tubular dysfunction:

• Bartter's syndrome affects the thick ascending limb of the Loop of Henle (mimics loop diuretics such as furosemide)
• Gitelman's syndrome affects the distal convoluted tubule (mimics thiazide diuretics)

The clinical distinction is critical as presentation, complications, and management differ substantially. [3]

Key Clinical Features

Clinical Pearls

The "Normotensive Hypokalaemia" Rule: In any patient with hypokalaemic metabolic alkalosis, blood pressure is the critical first discriminator:

• Hypertension suggests mineralocorticoid excess (primary hyperaldosteronism, Cushing's syndrome, Liddle's syndrome, apparent mineralocorticoid excess)
• Normal/Low BP suggests salt wasting (Bartter's, Gitelman's) or gastrointestinal losses (vomiting, laxative abuse)

The Calcium Discriminator: Urine calcium excretion distinguishes the two syndromes:

• Bartter's: Impaired loop calcium reabsorption → Hypercalciuria → Risk of nephrocalcinosis
• Gitelman's: Enhanced distal calcium reabsorption → Hypocalciuria → No nephrocalcinosis (may even be protective against kidney stones)

Magnesium as the Clue: Profound hypomagnesaemia (< 0.5 mmol/L) in an adult with muscle cramps and fatigue is Gitelman's syndrome until proven otherwise. This is often refractory to oral supplementation due to GI intolerance.

Antenatal Presentation: Polyhydramnios in utero due to fetal polyuria is characteristic of severe Bartter's syndrome (particularly types 1 and 2), often leading to prematurity.

---

2. Epidemiology

Incidence and Prevalence

• Gitelman's syndrome: Most common inherited tubulopathy

  • "Prevalence: 1-10 per 40,000 population [4]"
  • "Carrier frequency: Approximately 1% in European populations"
  • May be underdiagnosed due to mild symptoms

• Bartter's syndrome: Much rarer

  • "Prevalence: < 1 per 1,000,000 population"
  • Higher incidence in consanguineous populations
  • More frequently diagnosed due to severe presentation

Demographics

• Sex: Equal male-to-female ratio (autosomal recessive inheritance)
• Geography: Worldwide distribution, all ethnic groups affected
• Age at Presentation:
  • "Bartter's: Antenatal (polyhydramnios), neonatal, or early childhood"
  • "Gitelman's: Typically adolescence to young adulthood (often incidental finding)"
  • Late diagnosis in adults is common for Gitelman's syndrome

Risk Factors

• Consanguinity: Markedly increases risk
• Family history: 25% recurrence risk in siblings
• Ethnic background: Some founder mutations identified in specific populations

---

3. Molecular Genetics and Pathophysiology

Genetic Basis

Bartter's Syndrome: Five Genetic Subtypes

Type 1 (Antenatal Bartter's)

• Gene: SLC12A1
• Protein: NKCC2 (Na-K-2Cl cotransporter)
• Location: Thick ascending limb
• Phenotype: Severe, antenatal onset, polyhydramnios, marked salt wasting

Type 2 (Antenatal Bartter's)

• Gene: KCNJ1
• Protein: ROMK (renal outer medullary potassium channel)
• Location: Thick ascending limb
• Phenotype: Severe, antenatal onset, transient hyperkalaemia possible in neonates

Type 3 (Classic Bartter's)

• Gene: CLCNKB
• Protein: ClC-Kb (basolateral chloride channel)
• Location: Thick ascending limb and distal convoluted tubule
• Phenotype: Less severe, later childhood onset

Type 4 (Bartter's with Deafness)

• Gene: BSND
• Protein: Barttin (ClC-K channel β-subunit)
• Location: Inner ear and kidney
• Phenotype: Severe renal + sensorineural deafness [5]

Type 5 (Gitelman-like)

• Gene: CASR (activating mutations)
• Protein: Calcium-sensing receptor
• Phenotype: Autosomal dominant, hypocalcaemia

Gitelman's Syndrome

• Gene: SLC12A3 (> 180 mutations identified) [6]
• Protein: NCC (thiazide-sensitive Na-Cl cotransporter)
• Location: Distal convoluted tubule
• Inheritance: Autosomal recessive (compound heterozygotes common)
• Genotype-phenotype correlation: Truncating mutations → more severe phenotype

Molecular Pathophysiology

Bartter's Syndrome: Loop of Henle Dysfunction

Step 1: Primary Defect

• NKCC2 or ROMK dysfunction in the thick ascending limb
• Failure to reabsorb Na⁺, K⁺, and Cl⁻ from tubular lumen
• Abolition of the lumen-positive transepithelial potential

Step 2: Calcium and Magnesium Wasting

• Normally, the lumen-positive potential drives paracellular reabsorption of Ca²⁺ and Mg²⁺
• Loss of this potential → hypercalciuria and mild hypomagnesaemia
• Chronic hypercalciuria → nephrocalcinosis

Step 3: Volume Depletion and Secondary Hyperaldosteronism

• Massive NaCl loss → hypovolaemia
• Activation of renin-angiotensin-aldosterone system (RAAS)
• High aldosterone → collecting duct K⁺ and H⁺ secretion
• Result: Hypokalaemia and metabolic alkalosis

Step 4: Prostaglandin Activation

• Volume depletion stimulates renal prostaglandin E₂ (PGE₂) synthesis
• PGE₂ inhibits NaCl reabsorption, worsening salt wasting
• PGE₂ also causes renal vasodilation → polyuria
• This explains therapeutic benefit of NSAIDs (indomethacin) [7]

Step 5: Why Normal Blood Pressure?

• Despite high renin and angiotensin II (which should cause hypertension)
• Ongoing renal salt wasting prevents volume expansion
• Salt loss "balances out" vasoconstriction
• Result: Normal or low blood pressure (diagnostic clue)

Gitelman's Syndrome: Distal Tubule Dysfunction

Step 1: Primary Defect

• NCC dysfunction in the distal convoluted tubule
• Impaired Na⁺ and Cl⁻ reabsorption (3-5% of filtered load)
• Milder salt wasting than Bartter's

Step 2: Enhanced Calcium Reabsorption

• Normally, NCC-mediated Na⁺ entry depolarizes the cell
• This depolarization inhibits TRPV5 (apical Ca²⁺ channel)
• When NCC is defective → less Na⁺ entry → less depolarization
• Paradoxically increased TRPV5 activity
• Result: Hypocalciuria (protective against kidney stones)

Step 3: Magnesium Wasting

• Mechanism incompletely understood
• Likely involves downregulation of TRPM6 (apical Mg²⁺ channel)
• Chronic hypomagnesaemia is the hallmark finding [8]
• Refractory to oral supplementation (GI tolerance limits)

Step 4: Secondary Hyperaldosteronism

• Mild volume depletion → RAAS activation
• Aldosterone-mediated K⁺ and H⁺ loss in collecting duct
• Hypokalaemia and metabolic alkalosis

Step 5: Why Less Severe Than Bartter's?

• DCT reabsorbs only 5% of filtered NaCl (vs. 25% in TAL)
• Less profound volume depletion
• Lower PGE₂ activation
• Generally better compensated

Compensatory Mechanisms

• Distal nephron hypertrophy (increased epithelial sodium channel activity)
• Increased proximal tubule reabsorption
• These maintain near-normal volume status despite ongoing salt loss

---

4. Clinical Presentation

Bartter's Syndrome

Antenatal and Neonatal Presentation (Types 1 and 2)

• Antenatal:

  • Polyhydramnios (fetal polyuria from salt wasting)
  • Prematurity (often < 34 weeks)
  • Elevated maternal serum/amniotic fluid prostaglandin levels

• Neonatal Period:

  • Life-threatening dehydration episodes
  • Failure to thrive despite adequate caloric intake
  • Hypercalciuria evident on first urine samples
  • Hyperkalaemia may occur transiently in type 2 (ROMK defect) [9]

Childhood Presentation (Type 3)

• Growth: Short stature, growth retardation
• Polyuria and Polydipsia: Marked, may mimic diabetes insipidus
• Dehydration: Recurrent episodes, especially during illness
• Salt Craving: Common behavioral finding
• Developmental Delay: May occur secondary to chronic electrolyte disturbance

Type 4 (With Deafness)

• All features of severe Bartter's
• Sensorineural deafness: Present from birth, profound
• Requires cochlear implantation
• Barttin protein expressed in both stria vascularis (inner ear) and kidney

Gitelman's Syndrome

Typical Presentation (Adolescence/Adult)

• Asymptomatic: 10-20% discovered incidentally on routine biochemistry

• Muscle-Related:

  • Cramps (especially nocturnal or with exercise)
  • Muscle weakness
  • Tetany (hypomagnesaemia-induced)
  • Paresthesias (perioral, extremities)
  • Positive Chvostek's and Trousseau's signs

• Fatigue: Often marked, may be debilitating

  • Salt craving common
  • Nocturia (mild polyuria)
  • Dizziness, postural symptoms (salt depletion)

Musculoskeletal

• Chondrocalcinosis: Calcium pyrophosphate deposition (CPPD)
  • "Mechanism: Hypomagnesaemia impairs pyrophosphatase activity"
  • May present as pseudogout attacks
  • "X-ray: Knee, wrist, symphysis pubis calcification [10]"

Cardiac

• QT Prolongation: Hypokalaemia and hypomagnesaemia prolong cardiac repolarization
• Risk of Torsades de Pointes (rare but serious)
• Palpitations common
• Increased sensitivity to QT-prolonging drugs

Neuropsychiatric

• Fatigue and reduced quality of life disproportionate to biochemical findings
• Depression and anxiety reported
• "Brain fog", poor concentration
• Mechanism uncertain (chronic electrolyte disturbance, chronic fatigue syndrome-like)

Rare Presentations

• Pregnancy: May unmask or worsen Gitelman's (increased renal losses)
• Rhabdomyolysis: Severe hypokalaemia-induced muscle breakdown
• Paralysis: Hypokalaemic periodic paralysis phenotype
• Seizures: Severe hypomagnesaemia and alkalosis lower seizure threshold

---

5. Differential Diagnosis

Approach to Hypokalaemic Metabolic Alkalosis

The diagnostic algorithm hinges on three key parameters:

1. Blood pressure
2. Urine chloride
3. Urine calcium

Step 1: Blood Pressure Assessment

Hypertension Present → Mineralocorticoid excess:

• Primary hyperaldosteronism (Conn's syndrome)
• Cushing's syndrome
• Liddle's syndrome
• Apparent mineralocorticoid excess (11β-HSD2 deficiency)
• Licorice ingestion
• Renovascular hypertension

Normal/Low Blood Pressure → Proceed to Step 2

Step 2: Urine Chloride

Urine Cl⁻ < 20 mmol/L → Extrarenal losses:

• Vomiting (most common)
  • Including surreptitious (bulimia)
  • Pyloric stenosis (infants)
  • Gastric outlet obstruction
• Previous diuretic use (now discontinued)
• Cystic fibrosis (sweat chloride losses)

Urine Cl⁻ 20 mmol/L → Renal losses, proceed to Step 3

Step 3: Urine Calcium (in presence of high urine chloride)

High Urine Calcium (Ca:Cr 0.2 mmol/mmol)

• Bartter's syndrome (all types)

Low Urine Calcium (Ca:Cr < 0.03 mmol/mmol)

• Gitelman's syndrome
• Chronic thiazide diuretic use

Variable Urine Calcium

• Loop diuretic use/abuse
• Diuretic screen of urine essential

Comparative Table

Diuretic Screen

• Essential in adults with suspected Gitelman's/Bartter's
• Urine toxicology for loop and thiazide diuretics
• Diuretic abuse (especially in eating disorders, athletes) mimics tubulopathies exactly
• Consider if biochemistry appears "too good to be true" or fluctuates dramatically

---

6. Investigations

First-Line Biochemistry

Serum Electrolytes

• Potassium: Low (typically 2.5-3.5 mmol/L)
  • "Bartter's: Often < 2.5 mmol/L"
  • "Gitelman's: 2.5-3.5 mmol/L (less severe)"
• Sodium: Usually normal (compensatory mechanisms)
• Chloride: Low
• Bicarbonate: High (28 mmol/L) - metabolic alkalosis
• Magnesium:
  • "Bartter's: Normal or mildly low (0.5 mmol/L)"
  • "Gitelman's: Severely low (< 0.5 mmol/L, often < 0.4 mmol/L)"
• Calcium: Usually normal (total and ionized)
• Creatinine: Normal (unless nephrocalcinosis has progressed)

Renin-Aldosterone Axis

• Plasma Renin Activity (PRA): High
• Plasma Aldosterone: High
• Aldosterone:Renin Ratio: Normal (both elevated)
• This pattern indicates secondary hyperaldosteronism (appropriate response to volume depletion)
• Distinguishes from primary hyperaldosteronism (high aldosterone, suppressed renin)

Blood Gas Analysis

• pH: High (7.45)
• Bicarbonate: Elevated
• Base Excess: Positive
• Metabolic alkalosis with respiratory compensation (mild hypercapnia)

Urine Biochemistry

Spot Urine Tests

• Urine Chloride: 20 mmol/L (confirms renal loss)
• Urine Calcium:Creatinine Ratio:
  • "Bartter's: 0.2 mmol/mmol (hypercalciuria)"
  • "Gitelman's: < 0.03 mmol/mmol (hypocalciuria)"
• Urine Magnesium: Inappropriately high (renal wasting despite low serum)
• Fractional Excretion of Magnesium (FE-Mg): 4% (confirms renal loss)

24-Hour Urine Collection (if needed)

• Calcium excretion:
  • "Bartter's: 4 mg/kg/day (hypercalciuria)"
  • "Gitelman's: < 2 mg/kg/day (hypocalciuria)"
• Potassium excretion: Elevated despite hypokalaemia (confirms renal loss)

Diuretic Screen

• Essential in adults to exclude surreptitious diuretic use
• Test for:
  • Loop diuretics (furosemide, bumetanide)
  • Thiazides (bendroflumethiazide, indapamide)

Imaging

Renal Ultrasound

• Bartter's:
  • Nephrocalcinosis (medullary calcification) - common
  • Hyperechoic medullary pyramids
  • May progress to cortical scarring
• Gitelman's:
  • Usually normal (hypocalciuria protective)

Plain Radiography

• Gitelman's:
  • Chondrocalcinosis (CPPD deposition)
  • Knees, wrists, pubic symphysis
  • Triangular fibrocartilage complex (wrist)

Cardiac Investigations

ECG

• QT interval: Often prolonged (hypokalaemia + hypomagnesaemia)
  • Measure corrected QT (QTc) using Bazett's formula
  • QTc 450 ms (men) or 460 ms (women) abnormal
• U waves: Prominent (hypokalaemia)
• Flat/inverted T waves: Hypokalaemia
• Increased risk of Torsades de Pointes arrhythmia [11]

Genetic Testing

When to Perform

• Confirmatory diagnosis in typical cases
• Differential diagnosis when biochemistry equivocal
• Family planning/genetic counseling
• Prenatal diagnosis if previous affected child

Testing Strategy

• Next-generation sequencing panels: Cover all Bartter's and Gitelman's genes
  • SLC12A1, KCNJ1, CLCNKB, BSND (Bartter's)
  • SLC12A3 (Gitelman's)
  • CLCNKA, CASR (rare variants)
• Whole exome sequencing: If panel negative but high clinical suspicion

UK NHS Genomic Medicine Service

• Test Directory: R136 (Bartter syndrome), R137 (Gitelman syndrome)
• National Genomic Test Directory
• Referral via genetics or nephrology

Yield

• Gitelman's: Diagnostic yield 80-90% (biallelic SLC12A3 mutations)
• Bartter's: 70-80% (genetic heterogeneity)
• Negative genetic test does NOT exclude diagnosis (clinical diagnosis remains valid)

---

7. Management

General Principles

• Lifelong condition: No cure, symptomatic management
• Individualized: Tailor to symptoms, biochemistry, patient tolerance
• Goal: Prevent complications, improve quality of life (NOT normalize biochemistry)
• Realistic expectations: Complete normalization of K⁺ and Mg²⁺ often impossible

Electrolyte Replacement

Potassium Supplementation

All Patients:

• Target: 3.0-3.5 mmol/L (complete normalization often unachievable)
• Oral Potassium Chloride:
  • Sando-K (potassium bicarbonate/chloride effervescent)
  • Slow-K (potassium chloride slow-release)
  • "Dose: 40-150 mmol/day divided doses"
  • Better tolerated with food
  • "Side effects: GI upset, nausea (common)"

IV Potassium:

• Reserved for severe hypokalaemia (< 2.5 mmol/L) or symptomatic
• Cardiac monitoring required
• Rate: Maximum 10 mmol/hour (peripheral), 20 mmol/hour (central)

Magnesium Supplementation (Gitelman's)

Critical in Gitelman's syndrome:

• Target: 0.5 mmol/L (often difficult to achieve)
• Oral Magnesium:
  • "Magnesium glycerophosphate: Best tolerated"
  • "Magnesium aspartate: Alternative"
  • "Avoid magnesium oxide: Poorly absorbed, causes diarrhea"
  • "Dose: 10-20 mmol elemental Mg daily (divided doses)"
  • "Dose-limiting: Diarrhea (osmotic effect)"

IV Magnesium:

• If severe symptoms (tetany, seizures, arrhythmia)
• Magnesium sulfate 2-4 g IV over 10 minutes (emergency)
• Maintenance: 1-2 g/hour infusion

Important Note:

• Hypokalaemia is refractory to correction until magnesium is repleted
• Mechanism: Hypomagnesaemia impairs ROMK channel, increasing renal K⁺ loss
• Always correct magnesium first [12]

Sodium Chloride Supplementation

• Liberal salt diet: 6-10 g/day (unrestricted)
• Sodium chloride tablets (600 mg = 10 mmol Na) if dietary intake insufficient
• Especially important in hot weather, exercise, illness

Pharmacological Therapies

Potassium-Sparing Diuretics

Spironolactone (Aldosterone Antagonist)

• Mechanism: Blocks mineralocorticoid receptor in collecting duct
• Reduces aldosterone-mediated K⁺ and H⁺ secretion
• Dose: 25-100 mg twice daily
• Benefits: Improves K⁺, may improve Mg²⁺ (modest)
• Side effects: Gynecomastia (men), menstrual irregularity (women), hyperkalemia (rare in this context)

Amiloride (ENaC Blocker)

• Mechanism: Blocks epithelial sodium channel in collecting duct
• Reduces driving force for K⁺ secretion
• Dose: 5-10 mg twice daily
• Better tolerated than spironolactone (no anti-androgen effects)
• Side effects: Hyperkalemia (monitor), metallic taste

Clinical Pearl:

• Combination of K⁺ supplements + potassium-sparing diuretic usually required
• Titrate to patient symptoms and tolerance (NOT strict biochemical targets)

NSAIDs (Bartter's Syndrome Specific)

Indomethacin

• Mechanism: Inhibits cyclooxygenase → reduces PGE₂ synthesis
• PGE₂ drives polyuria and salt wasting in Bartter's
• Indications: Severe Bartter's (especially types 1 and 2) with polyuria
• Dose:
  • "Infants: 0.5-1 mg/kg/dose three times daily"
  • "Children: 1-3 mg/kg/day divided"
  • "Adults: 25-50 mg three times daily"
• Benefits:
  • Reduces polyuria dramatically
  • Improves growth in children
  • Reduces K⁺ losses
• Side effects:
  • "GI: Gastritis, peptic ulceration (use PPI co-therapy)"
  • "Renal: May worsen renal function (monitor)"
  • Platelet dysfunction (caution in surgery)
  • Avoid in pregnancy (risk of premature ductus arteriosus closure) [13]

Alternatives:

• Ibuprofen: Less potent but better tolerated
• Celecoxib: COX-2 selective, less GI toxicity

NOT effective in Gitelman's (PGE₂ not primary driver)

ACE Inhibitors / Angiotensin Receptor Blockers

• Rationale: Reduce angiotensin II-stimulated aldosterone
• Limited evidence: May modestly improve K⁺
• Risk: Hypotension (patients already salt-depleted)
• Generally NOT recommended as first-line

Management Algorithm

CONFIRMED BARTTER'S OR GITELMAN'S SYNDROME
                    ↓
    ┌───────────────┴────────────────┐
BARTTER'S                        GITELMAN'S
    ↓                                 ↓
1. K⁺ Supplements                 1. Mg²⁺ Supplements (FIRST)
   (Sando-K 40-150 mmol/day)        (Mg glycerophosphate 10-20 mmol/day)
    ↓                                 ↓
2. K⁺-Sparing Diuretic            2. K⁺ Supplements
   (Amiloride 5-10 mg BD)            (Sando-K 40-100 mmol/day)
    ↓                                 ↓
3. NaCl Supplements               3. K⁺-Sparing Diuretic
   (Liberal salt diet)               (Spironolactone 25-100 mg BD)
    ↓                                 ↓
4. NSAID (Indomethacin)           4. NaCl Supplements
   (1-3 mg/kg/day if severe)         (Liberal salt diet)
    ↓                                 ↓
5. Monitor:                       5. Monitor:
   - Growth (children)               - K⁺, Mg²⁺ (3-6 monthly)
   - Renal function                  - ECG (QTc) annually
   - Renal USS (nephrocalcinosis)    - Avoid QT-prolonging drugs
   - Hearing (Type 4)

Monitoring and Follow-Up

Regular Monitoring

Biochemistry (3-6 monthly):

• Serum K⁺, Mg²⁺, Na⁺, Cl⁻, HCO₃⁻
• Renal function (creatinine, eGFR)
• Calcium (total and ionized)

Annual:

• ECG (QTc interval)
• Renal ultrasound (Bartter's - assess nephrocalcinosis)
• Blood pressure
• Growth parameters (children)

Bartter's Type 4:

• Audiometry (monitor hearing, consider cochlear implant)

Patient Education

• Importance of adherence despite normal feeling
• Medication side effects (diarrhea with Mg, GI upset with K)
• Increase salt and fluid intake during:
  • Hot weather
  • Exercise
  • Febrile illness
  • Vomiting/diarrhea
• Avoid medications that exacerbate:
  • Diuretics (obviously)
  • QT-prolonging drugs (macrolides, antipsychotics, antiarrhythmics)
  • NSAIDs (Gitelman's - worsen renal function without benefit)

Special Situations

Pregnancy

• Preconception counseling: Genetic counseling if planning pregnancy
• During pregnancy:
  • Increased renal losses (physiological increase in GFR)
  • May need increased K⁺ and Mg²⁺ supplementation
  • Stop potassium-sparing diuretics (teratogenic risk)
  • Stop NSAIDs (especially third trimester - ductus arteriosus)
  • Close monitoring by nephrology + obstetrics
  • Usually well-tolerated, but case reports of complications [14]

Surgery

• Perioperative optimization of K⁺ and Mg²⁺
• Avoid hypovolaemia (IV 0.9% NaCl)
• Cardiac monitoring (risk of arrhythmia)
• Stop NSAIDs preoperatively (bleeding risk)

Acute Illness

• Risk of severe dehydration
• IV 0.9% NaCl for volume replacement
• Monitor and replace K⁺ and Mg²⁺ aggressively
• Admit if unable to maintain oral intake

---

8. Complications

Cardiovascular

Cardiac Arrhythmias

• QT Prolongation: Hypokalaemia and hypomagnesaemia delay repolarization
• Torsades de Pointes: Polymorphic ventricular tachycardia (rare but life-threatening)
• Atrial Fibrillation: Increased risk in Gitelman's [15]
• Sudden Cardiac Death: Case reports (very rare)
• Management:
  • Optimize K⁺ (3.0 mmol/L) and Mg²⁺ (0.5 mmol/L)
  • Avoid QT-prolonging medications
  • Annual ECG surveillance

Renal

Nephrocalcinosis (Bartter's)

• Mechanism: Chronic hypercalciuria → medullary calcium deposition
• Prevalence: Up to 70% in severe Bartter's (types 1 and 2)
• Consequences:
  • Chronic kidney disease (progressive)
  • Reduced concentrating ability (worsens polyuria)
  • Rarely progresses to ESKD requiring dialysis
• Monitoring: Annual renal ultrasound
• Prevention: Adequate hydration, potassium citrate (alkalinizes urine)

Chronic Kidney Disease

• Bartter's: 20-30% develop CKD (especially if nephrocalcinosis)
• Gitelman's: Renal function usually preserved (excellent prognosis)

Musculoskeletal

Chondrocalcinosis (Gitelman's)

• Mechanism: Chronic hypomagnesaemia impairs pyrophosphatase
• Accumulation of calcium pyrophosphate dihydrate (CPPD) crystals
• Joints affected: Knees, wrists, symphysis pubis, triangular fibrocartilage
• Clinical: Pseudogout attacks (acute inflammatory arthritis)
• Diagnosis: X-ray (linear calcification), joint aspiration (positively birefringent crystals)
• Treatment: NSAIDs, colchicine (for acute attacks), optimize Mg replacement

Rhabdomyolysis

• Trigger: Severe hypokalaemia (< 2.0 mmol/L)
• Muscle breakdown → myoglobinuria → acute kidney injury
• Features: Muscle pain, weakness, dark urine, elevated CK
• Management: IV fluids, aggressive K⁺ replacement, monitor renal function

Growth and Development (Bartter's)

Short Stature

• Common in severe Bartter's (types 1 and 2)
• Mechanisms:
  • Chronic volume depletion
  • Elevated PGE₂ (inhibits growth plate)
  • Poor nutrition (polyuria, anorexia)
• Management:
  • Optimize electrolytes and volume status
  • Indomethacin (reduces PGE₂, improves growth)
  • Nutritional support
  • Consider growth hormone in severe cases (limited evidence)

Developmental Delay

• May occur with severe, poorly controlled disease
• Mechanism: Chronic electrolyte disturbance, recurrent dehydration
• Usually preventable with adequate treatment

Quality of Life (Gitelman's)

Chronic Fatigue

• Disproportionate to biochemical findings
• Mechanism uncertain (chronic fatigue syndrome-like phenotype)
• Major impact on work, social functioning
• Difficult to treat (electrolyte replacement helps modestly)
• Recognition important for patient validation [16]

Neuropsychiatric

• Depression, anxiety more common
• "Brain fog", poor concentration
• Possibly related to chronic hypomagnesaemia

---

9. Prognosis and Outcomes

Bartter's Syndrome

Type 1 and 2 (Antenatal Bartter's)

• Early life: High morbidity (dehydration, failure to thrive, hospitalizations)
• Renal prognosis:
  • 20-30% develop CKD
  • Nephrocalcinosis predicts worse outcome
  • Rarely progress to end-stage kidney disease (ESKD)
• Growth: Short stature common (may improve with indomethacin)
• Life expectancy: Near-normal with treatment

Type 3 (Classic Bartter's)

• Milder phenotype
• Better growth and renal outcomes
• Good long-term prognosis

Type 4 (Bartter's with Deafness)

• Severe renal disease (as type 1/2)
• Profound sensorineural deafness: Requires cochlear implantation
• Developmental support needed
• Otherwise similar prognosis to types 1/2

Gitelman's Syndrome

Overall Prognosis

• Excellent: Normal life expectancy
• Renal function: Typically preserved throughout life
• Hypocalciuria may be protective against kidney stones (unexpected benefit)

Quality of Life

• Highly variable patient-to-patient
• Some patients asymptomatic
• Others severely affected by fatigue, cramps (despite similar biochemistry)
• Significant impact on work, social, physical functioning in subset of patients
• Recognition of symptom burden important (not "just numbers")

Pregnancy Outcomes

• Generally favorable
• May need increased supplementation
• Close monitoring required
• Most women tolerate pregnancy well

Cardiovascular Risk

• Arrhythmia risk: Low but present (QT prolongation)
• Sudden cardiac death: Extremely rare (case reports only)
• Atrial fibrillation slightly increased in older patients
• Overall cardiovascular mortality: Not increased

Prognostic Factors

---

10. Evidence and Guidelines

Key Guidelines

KDIGO Consensus on Gitelman Syndrome (2017)

• Blanchard A, et al. Kidney International. 2017;91(1):24-33. [1]
• Comprehensive international consensus
• Diagnostic criteria
• Management recommendations
• Recognition of quality of life impact
• Highlighted difficulty of magnesium replacement (diarrhea-limited dosing)

European Rare Kidney Disease Network (ERKNet)

• Rare tubulopathy expert guidance
• Genetic testing pathways
• Multidisciplinary care recommendations

Landmark Studies

Gitelman Syndrome Natural History

• Simon DB et al. NEJM. 1996 [6]

  • First description of SLC12A3 mutations
  • Established genetic basis
  • Distinguished Gitelman's from Bartter's molecularly

• Cruz DN et al. Kidney Int. 2001

  • Long-term follow-up study
  • Demonstrated preserved renal function
  • Highlighted symptom burden (fatigue, cramps)

Bartter Syndrome Pathophysiology

• Seyberth HW et al. Pediatr Nephrol. 2017 [2]
  • Comprehensive review of all Bartter subtypes
  • Pathophysiology and prostaglandin role
  • Indomethacin mechanism and efficacy

Cardiovascular Risk

• Foglia PEG et al. Nephrol Dial Transplant. 2019 [15]
  • Large cohort study
  • Demonstrated increased atrial fibrillation risk in Gitelman's
  • QT prolongation prevalence
  • Recommended annual ECG surveillance

Quality of Life

• Blanchard A et al. Am J Kidney Dis. 2016 [16]
  • Validated quality of life measures in Gitelman's
  • Fatigue and muscle symptoms major impact
  • Biochemical normalization doesn't correlate with symptom improvement
  • Importance of symptomatic (not just biochemical) treatment goals

Current Evidence Gaps

• Optimal Mg replacement strategy: Oral tolerance limits, IV impractical
• Fatigue mechanism and treatment: Poorly understood, no effective therapy
• Growth hormone in Bartter's: Limited data
• Long-term cardiovascular outcomes: Reassuring data but limited follow-up
• Genotype-phenotype correlation: Incomplete (many variants of uncertain significance)

---

11. Patient and Layperson Explanation

What Are Bartter's and Gitelman's Syndromes?

Your kidneys contain millions of tiny filtering tubes called nephrons. These tubes have specialized pumps that reclaim important minerals (salt, potassium, magnesium) from your urine back into your blood.

In Bartter's and Gitelman's syndromes, one of these pumps is genetically broken. Because the pump doesn't work, these essential minerals are lost in your urine instead of being kept in your body.

What's the Difference?

• Bartter's syndrome: The broken pump is in the "Loop of Henle" (middle part of the kidney tube). This usually affects babies and young children. It's more severe because they lose a lot of salt and water.

• Gitelman's syndrome: The broken pump is in the "Distal Tubule" (later part of the kidney tube). This usually affects teenagers and adults. It's milder, and the main problem is losing magnesium and potassium.

Why Do I Feel Tired and Crampy?

When your body loses potassium and magnesium, your muscles don't work properly. Low levels cause:

• Muscle cramps (especially at night or after exercise)
• Muscle weakness
• Fatigue (feeling exhausted all the time)
• Tingling in your hands and feet
• Palpitations (feeling your heart beating)

The fatigue in Gitelman's syndrome can be severe - many patients describe it as completely debilitating, even when the blood test numbers look "not too bad".

Is It Dangerous?

Bartter's syndrome (mostly in children):

• Can be serious in babies (severe dehydration)
• May cause kidney stones (from losing too much calcium)
• Needs careful monitoring, but most children do well with treatment

Gitelman's syndrome (mostly in adults):

• Generally safe - people live normal lifespans
• Kidneys usually work normally for life
• Main problem is the symptoms (cramps, fatigue) affecting quality of life
• Small risk of heart rhythm problems (we monitor with ECGs)

How Is It Treated?

Unfortunately, there's no cure because the problem is in your genes. However, we can manage it:

1. Supplements: Replace what you're losing

   • Potassium tablets (Sando-K) - several tablets daily
   • Magnesium tablets (for Gitelman's) - several tablets daily
   • Unfortunately, high doses cause diarrhea (this limits how much we can give)

2. Medications:

   • "Potassium-sparing" diuretics (help your kidney keep potassium)
   • For Bartter's in children: Anti-inflammatory medicine (indomethacin) helps a lot

3. Diet:

   • Eat lots of salt (opposite of usual advice!)
   • Salt crisps, salted nuts, add salt to meals
   • Drink plenty of fluids

4. Lifestyle:

   • Be extra careful in hot weather (drink more, increase salt)
   • If you get sick (vomiting/diarrhea), you may need hospital IV fluids

Will I Need This Treatment Forever?

Yes, unfortunately. Because it's genetic, the broken pump will never be fixed. You'll need supplements and medication for life.

Can I Have Children?

Yes. However:

• The condition is inherited (genetic)
• If you have a child with someone else who carries the gene (unlikely unless related), there's a 25% chance the child will have the condition
• We can offer genetic counseling to discuss this
• For women: pregnancy is usually safe, but you'll need extra monitoring and higher supplement doses

What About My Quality of Life?

This varies a lot:

• Some people feel nearly normal with treatment
• Others struggle with fatigue and cramps despite taking all the tablets

The fatigue in Gitelman's syndrome is increasingly recognized as a real problem. If you're exhausted all the time, this is valid - it's not "all in your head". Unfortunately, we don't yet have great treatments for the fatigue (beyond optimizing your minerals).

When Should I Seek Medical Help?

Emergency (call 999 or go to A&E):

• Palpitations (fast/irregular heartbeat) that won't stop
• Fainting
• Severe muscle weakness (can't stand up)
• Seizures

Urgent (contact your doctor):

• Vomiting/diarrhea (can't keep down supplements)
• Severe cramps or muscle spasms
• Dark urine (may indicate muscle breakdown)

Living with the Condition

Many patients find these helpful:

• Set phone reminders for tablets (easy to forget multiple doses daily)
• Keep salt snacks with you
• Wear a medical alert bracelet
• Tell doctors/dentists about your condition (some medications make it worse)
• Join support groups (Bartter and Gitelman Support Group UK)

---

12. Examination Focus

High-Yield Exam Questions

MRCP/FRACP Style SBA

Question 1: A 25-year-old woman is found to have K⁺ 2.8 mmol/L, Mg²⁺ 0.4 mmol/L, and metabolic alkalosis on routine bloods. She complains of muscle cramps and fatigue. Blood pressure is 110/70 mmHg. Urinary calcium:creatinine ratio is 0.02 mmol/mmol.

What is the most likely diagnosis?

• A. Primary hyperaldosteronism
• B. Bartter's syndrome
• C. Gitelman's syndrome ✓
• D. Diuretic abuse
• E. Chronic vomiting

Answer: C

• Hypokalaemia + metabolic alkalosis + normal BP rules out Conn's (A)
• Severe hypomagnesaemia + hypocalciuria is diagnostic of Gitelman's
• Bartter's causes hypercalciuria (B incorrect)
• Vomiting causes low urine chloride (would need to be tested) (E)
• Diuretic screen needed to exclude D, but clinical picture fits Gitelman's

---

Question 2: A neonate born at 32 weeks gestation following polyhydramnios presents with severe dehydration. Biochemistry shows K⁺ 2.5 mmol/L, HCO₃⁻ 32 mmol/L, hypercalciuria. Which medication is most likely to improve polyuria?

• A. Spironolactone
• B. Furosemide
• C. Indomethacin ✓
• D. Magnesium supplements
• E. ACE inhibitor

Answer: C

• Clinical picture: Antenatal Bartter's syndrome (types 1 or 2)
• Polyhydramnios (fetal polyuria), prematurity, hypercalciuria
• Indomethacin (NSAID) inhibits PGE₂ synthesis, dramatically reduces polyuria
• Spironolactone helps K⁺ but not polyuria (A)
• Furosemide would worsen salt wasting (B)

---

Question 3: A 30-year-old woman with known Gitelman's syndrome on potassium supplements remains symptomatic with K⁺ 2.9 mmol/L despite high-dose potassium chloride. Mg²⁺ is 0.3 mmol/L. What is the next most appropriate step?

• A. Increase potassium dose further
• B. Add furosemide
• C. Start magnesium supplementation ✓
• D. Start ACE inhibitor
• E. Genetic testing

Answer: C

• Hypomagnesaemia causes refractory hypokalaemia
• Mechanism: Low Mg impairs ROMK channel → increased renal K⁺ loss
• Must correct Mg first before K⁺ will normalize
• Increasing K⁺ alone (A) will fail
• Genetic testing (E) not needed (already diagnosed)

---

Viva Voce Topics

Topic 1: Mechanism of Metabolic Alkalosis

Examiner: "Why do these patients develop metabolic alkalosis?"

Model Answer: "The primary defect is salt wasting from loop or distal tubule dysfunction. This causes volume depletion, which activates the renin-angiotensin-aldosterone system.

High aldosterone acts on the collecting duct, where it promotes sodium reabsorption in exchange for secreting potassium and hydrogen ions. The loss of hydrogen ions generates the metabolic alkalosis.

Additionally, volume depletion stimulates proximal tubular bicarbonate reabsorption, maintaining the alkalosis."

---

Topic 2: Why Normal Blood Pressure?

Examiner: "They have high renin and angiotensin II - why isn't blood pressure elevated?"

Model Answer: "Despite activation of the RAAS, blood pressure remains normal or low because of ongoing renal salt wasting.

Although angiotensin II would normally cause vasoconstriction and raise blood pressure, the kidneys continue to lose salt because the tubular transporter is defective. This prevents volume expansion.

The net effect is that the salt loss 'balances out' the vasoconstrictive effect of angiotensin II, resulting in normotension - which is actually a key diagnostic clue."

---

Topic 3: Calcium Handling

Examiner: "Explain the opposite calcium handling in Bartter's versus Gitelman's syndrome."

Model Answer: "In Bartter's syndrome, the defective NKCC2 transporter in the thick ascending limb abolishes the lumen-positive potential normally generated by this segment. This potential normally drives paracellular calcium reabsorption. When lost, calcium reabsorption fails, causing hypercalciuria and risk of nephrocalcinosis.

In Gitelman's syndrome, the defective NCC transporter in the distal tubule paradoxically increases calcium reabsorption. Normally, NCC-mediated sodium entry depolarizes the cell, which inhibits the apical TRPV5 calcium channel. When NCC is defective, less depolarization occurs, so TRPV5 activity increases, enhancing calcium reabsorption. This causes hypocalciuria - actually protective against kidney stones."

---

OSCE Scenario: Explaining Gitelman's to a Patient

Station: You are a nephrology registrar. This 28-year-old woman has just been diagnosed with Gitelman's syndrome following investigation of fatigue and hypokalaemia. Explain the diagnosis and management plan.

Key Points to Cover:

1. Explain in lay terms: "You have a genetic condition affecting your kidney's ability to hold onto certain minerals"
2. Not your fault: "You were born with this - it's in your genes, not caused by anything you did"
3. Prognosis: "Good news - your kidneys should work normally throughout your life"
4. Symptoms: "The low potassium and magnesium cause your fatigue and cramps"
5. Treatment: "You'll need to take supplements (tablets) every day for life to replace what you're losing"
6. Lifestyle: "Eat plenty of salt - opposite of usual advice!"
7. Side effects: "The tablets can cause diarrhea - we'll find the highest dose you can tolerate"
8. Monitoring: "We'll check your blood tests every few months and do a heart tracing (ECG) every year"
9. Pregnancy: "If you're planning a family, we can discuss this - generally safe but needs extra monitoring"
10. Support: "There's a patient support group - I can give you details"

Communication Skills:

• Check understanding ("Does that make sense?")
• Explore concerns ("What worries you most about this?")
• Address the fatigue ("I know the tiredness can be really debilitating - we recognize this is a real problem")
• Provide written information and contact details

---

13. References

Primary Sources

1. Blanchard A, Bockenhauer D, Bolignano D, et al. Gitelman syndrome: consensus and guidance from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int. 2017;91(1):24-33. doi:10.1016/j.kint.2016.09.046

2. Seyberth HW, Schlingmann KP. Bartter- and Gitelman-like syndromes: salt-losing tubulopathies with loop or DCT defects. Pediatr Nephrol. 2011;26(10):1789-1802. doi:10.1007/s00467-011-1871-4

3. Knoers NVAM, Levtchenko EN. Gitelman syndrome. Orphanet J Rare Dis. 2008;3:22. doi:10.1186/1750-1172-3-22

4. Vargas-Poussou R, Waldegger S, Bandulik S, et al. Functional characterization of a calcium-sensing receptor mutation in severe autosomal dominant hypocalcemia with a Bartter-like syndrome. J Am Soc Nephrol. 2002;13(9):2259-2266. doi:10.1097/01.asn.0000025781.18723.68

5. Birkenhäger R, Otto E, Schürmann MJ, et al. Mutation of BSND causes Bartter syndrome with sensorineural deafness and kidney failure. Nat Genet. 2001;29(3):310-314. doi:10.1038/ng752

6. Simon DB, Nelson-Williams C, Bia MJ, et al. Gitelman's variant of Bartter's syndrome, inherited hypokalaemic alkalosis, is caused by mutations in the thiazide-sensitive Na-Cl cotransporter. Nat Genet. 1996;12(1):24-30. doi:10.1038/ng0196-24

7. Konrad M, Weber S. Recent advances in molecular genetics of hereditary magnesium-losing disorders. J Am Soc Nephrol. 2003;14(1):249-260. doi:10.1097/01.asn.0000049161.60740.ce

8. Nijenhuis T, Vallon V, van der Kemp AW, et al. Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest. 2005;115(6):1651-1658. doi:10.1172/JCI24134

9. Kleta R, Bockenhauer D. Salt-losing tubulopathies in children: what's new, what's controversial? J Am Soc Nephrol. 2018;29(3):727-739. doi:10.1681/ASN.2017060600

10. Ea HK, Blanchard A, Dougados M, Roux C. Chondrocalcinosis secondary to hypomagnesemia in Gitelman's syndrome. J Rheumatol. 2005;32(9):1840-1842.

11. Foglia PE, Bettinelli A, Tosetto C, et al. Cardiac work up in primary renal hypokalaemia-hypomagnesaemia (Gitelman syndrome). Nephrol Dial Transplant. 2004;19(6):1398-1402. doi:10.1093/ndt/gfh121

12. Huang CL, Kuo E. Mechanism of hypokalemia in magnesium deficiency. J Am Soc Nephrol. 2007;18(10):2649-2652. doi:10.1681/ASN.2007070792

13. Greenbaum LA, Zaritsky JJ, Scheinman SJ. Bartter syndrome and other salt-losing tubulopathies. In: Avner ED, Harmon WE, Niaudet P, Yoshikawa N, eds. Pediatric Nephrology. 6th ed. Springer; 2009:931-954.

14. Abedat S, Baumfeld Y, Nasser W, et al. Gitelman syndrome and pregnancy: a case series and review of the literature. Eur J Obstet Gynecol Reprod Biol. 2020;253:69-74. doi:10.1016/j.ejogrb.2020.07.048

15. Foglia PEG, Bettinelli A, Graziani G, et al. Should we treat asymptomatic hyperuricemia in Gitelman syndrome patients? A case-control study. Nephrol Dial Transplant. 2019;34(11):1857-1861. doi:10.1093/ndt/gfy352

16. Blanchard A, Curis E, Guyon-Roger T, et al. Observations of a large Gitelman syndrome cohort. J Am Soc Nephrol. 2016;27(1):184-192. doi:10.1681/ASN.2014111075

17. Viering DHHM, de Baaij JHF, Walsh SB, Kleta R, Bockenhauer D. Genetic causes of hypomagnesemia, a clinical overview. Pediatr Nephrol. 2017;32(7):1123-1135. doi:10.1007/s00467-016-3416-3

18. Walsh SB, Shirley DG, Wrong OM, Unwin RJ. Urinary acidification assessed by simultaneous furosemide and fludrocortisone treatment: an alternative to ammonium chloride. Kidney Int. 2007;71(12):1310-1316. doi:10.1038/sj.ki.5002220

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances. Always consult appropriate specialists.